TY  - JOUR
AU  - Blanquez-Martinez, David
AU  - Diaz-Villamarin, Xando
AU  - Garcia-Rodriguez, Sonia
AU  - Antunez-Rodriguez, Alba
AU  - Pozo-Agundo, Ana
AU  - Martinez-Gonzalez, Luis Javier
AU  - Muñoz-Avila, Jose Ignacio
AU  - Davila-Fajardo, Cristina Lucia
PY  - 2022
DO  - 10.3390/pharmaceutics14081555
SN  - 1999-4923
UR  - http://hdl.handle.net/10668/21556
T2  - Pharmaceutics
AB  - A severe form of myopia defined as pathologic/high myopia is the main cause of visual impairment and one of the most frequent causes of blindness worldwide. It is characterized by at least 6 diopters or axial length (AL) of eyeball > 26 mm and...
LA  - en
KW  - FLT1
KW  - KDR
KW  - VEGFR
KW  - anti-VEGF
KW  - myopia
KW  - pharmacogenetics
KW  - precision medicine
KW  - ranibizumab
KW  - Ranibizumab
KW  - Humans
KW  - Vascular Endothelial Growth Factor A
KW  - Retrospective Studies
KW  - Polymorphism, Single Nucleotide
KW  - Vascular Endothelial Growth Factor Receptor-1
KW  - Follow-Up Studies
KW  - Choroidal Neovascularization
KW  - Myopia
KW  - Macular Degeneration
KW  - Genotype
KW  - Visual Acuity
KW  - Vision Disorders
KW  - Blindness
TI  - Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients.
TY  - research article
VL  - 14
ER  -